A-Shares Market Close: Three Major Indices Retreat After Rally, CRO and Pharmaceutical Sectors Stage Strong Rebound

China's Midday Market: Shanghai Composite Up 0.42%, ChiNext Rises 1.61% as Pharma and Computing Power Surge

Pharmaceutical Research Surpasses Semiconductor in Interest, Innovative Drug Sector Retreats, Huabao Fund's Hong Kong Biotech ETF Falls Below Key Moving Average, CXO Shows Resilience with WuXi Companies Rising Against the Trend

August Fund Launch Supply Dips, Healthcare Sector Attracts Contrarian Investment

China A-Share Key Announcements: A 5x Surge Stock Issues Urgent Clarification; Six-Day Limit-Up Pharma Leader Warns of Risks

Morning Session Sees Market Divergence With ChiNext Up 1.41%, MLCC and Pharmaceuticals Lead Gains

Gold Jewelry Leads Consumer Recovery, AI-Driven Healthcare Continues Strong Momentum

Market Trends Consolidate: Multiple Healthcare Stocks Display 'Pair' Patterns, Here's What It Could Mean

Record-Breaking Surge: WuXi Apptec Sets New Benchmarks, Reviving the Innovative Drug Sector’s Momentum? A New QDII Fund Launches to Capture the Opportunity

After 5 Months, Huabao Fund's Medical ETF (512170) Reclaims the 200-Day Moving Average! Wuxi Apptec A-Shares Break Through the Previous Bull Market Peak of the Pharmaceutical Sector, Hitting an 8-Year All-Time High

New stock preview: Second filing to Hong Kong Exchange, cash-strapped Xinyi Pharmaceutical faces challenges justifying its 1.5 billion valuation

19 Healthcare Sector Funds Post Over 10% Gains Year-to-Date

Expert Analysis: Guotai Fund's Qiu Xiaoxu Says Innovation Drug Exports Remain Strong, Three Investment Themes to Guide Healthcare Sector Strategy

Hong Kong Stock Alert | TRANSCENTA-B Surges Over 11% Pre-Noon, Plans to Sell CDMO Assets for 190 Million Yuan

Behind Ai Luming's Detention: The Capital Chaos of Humanwell Healthcare's Former Owner and Lingering Company Risks

WuXi Bio Co., Ltd. gains nearly 6% in early trading, plans to acquire ChuangSheng Pharma's process development and manufacturing base in Hangzhou

Healthcare emerges as top non-AI sector for investment rotation

Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306

Arbitration Uncertainty Resolved as Phase 3 Data Readout Nears; 3D189 Rights for 3D Medicines Face Value Reassessment

Guangzhou Xinji Medical Files Second Hong Kong IPO Application: Emerging Clinical and Governance Challenges